Affimed (NASDAQ:AFMD) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on AFMD. HC Wainwright restated a buy rating and set a $5.00 price objective on shares of […]